Du är här

2016-02-25

Ablynx: ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS

REGULATED INFORMATION

Key value drivers in pre-clinical and clinical development are progressing
well

Conference call and webcasttoday at 4pm CET/10am EST

GHENT, Belgium, 25 February 2016 - Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced its financial results for 2015, which have been prepared in
accordance with IFRS as adopted by the European Union.

* Total revenues of €77.5 million (+57%); cash position of €236.2 million
(+15%), strengthened by the successful placement of 5-year convertible
bonds (raising €100 million; 3.25% coupon rate and 26.5% conversion rate)
* Net cash burn of €67.2 million(1), an improvement over the previously
guided range of €70-80 million
* R&D highlights: initiated 1 Phase III study and 3 Phase II studies to
include a total of over 900 patients; completed recruitment of 35 infants
in the Phase I/IIa RSV study; completed recruitment of 345 patients in the
Phase IIb combination study with ALX-0061 in RA patients; initiated 14 new
discovery programmes both proprietary and as part of pharmaceutical
collaborations; achieved the first pre-clinical proof-of-concept with a
bi-specific Nanobody in the immuno-oncology collaboration with Merck&Co.,
Inc.
* Signed 3 new pharmaceutical partnerships and extended 2 existing
collaborations
* Significant catalysts anticipated in 2016 with a number of potential
pre-clinical/clinical milestones and several important clinical trial
read-outs

"We are very pleased with our strong performance in 2015 with excellent
progress reported in all areas,"said Dr Edwin Moses, CEO of Ablynx
. "Our product pipeline is advancing well and now includes more than 40
proprietary and partnered programmes, with our first Nanobody product
expected to be launched in 2018. We remain focused on delivering sustainable
value to all our stakeholders and look forward to an exciting year with
multiple pre-clinical, clinical and commercial catalysts across our extensive
pipeline."

Financial highlights

------------------------------------------------------------------
| (€ million) FY 2015 FY 2014 Variance |
| Total revenue and grant income 77.5 49.3 57% |
| R&D income 76.8 47.7 61% |
| Grants 0.7 1.6 (56%) |
| Operating expenses (94.5) (65.5) 44% |
| R&D (83.1) (54.5) 52% |
| G&A (11.4) (11.0) 4% |
| Operating result (17.0) (16.2) 5% |
| Net financial result (37.6) 3.5 >100% |
| Net result (54.5) (12.7) >100% |
| Net cash flow (67.2)(1) (34.1)(3) 97% |
| Cash(5)at 31 December 236.2(2) 206.2(4) 15% |
------------------------------------------------------------------
(1) excluding €97.2 million net proceeds from the convertible
bonds (which raised €100 million, announced on 20 May 2015)

(2) including €1.6 million in restricted cash

(3) excluding €39.9 million net proceeds from the private
placement (which raised €41.7 million, announced 30 June 2014)

(4) including €2.0 million in restricted cash

(5) defined as liquidity position in the cash flow statement

To read the full press release, including the outlook 2016, please click on
the link below.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than40 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, immuno-oncology,
oncology and respiratory disease. The Company has collaborations with
multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Genzyme, Merck&Co., Inc., Merck KGaA, Novartis, Novo Nordisk and
Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Instinctif Partners:

Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx@instinctif.com

Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx@instinctif.com

complete version of the press release
http://hugin.info/137912/R/1989045/730451.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1989045

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.